

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

ESMOND *et al.*

Appl. No. 09/394,712

Filed: September 13, 1999

For: **Method for Treating or  
Preventing Alzheimer's Disease**



Art Unit: 1614

Examiner: Kim. V.

Atty. Docket: 0609.4440002

RECEIVED

NOV 29 2000

TECH CENTER 1600/2C

J/B  
A Harmon  
12/2/00

**Amendment And Reply Under 37 C.F.R. § 1.111**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In reply to the Office Action dated September 25, 2000, (PTO Prosecution File Wrapper Paper No. 6), Applicants submit the following Amendment and Remarks.

***Amendments***

***In the Claims:***

Please cancel claims 3, 4, 5 and 6 without prejudice or disclaimer to the subject matter therein.

Please amend the following claims:

*1. (Twice amended) A method for the treatment [or prevention] of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of an agent which increases the insulin sensitivity of the human, with the proviso that said agent is not insulin-like growth factor or a dopamine agonist.*

*4. (Once amended) The method of claim [6] ~~25~~, wherein said thiazolidinedione is*

*troglitazone.*

11/27/2000 SSESWE1 00000078 09394712

01 FC:203  
02 FC:202

9.00 DP  
40.00 DP